MAUNA KEA TECHNOLOGIES (EPA:MKEA) Mauna Kea Technologies : Surgeons at University of Florida evaluate use of Cellvizio during partial and radical nephrectomies

Transparency directive : regulatory news

17/09/2015 18:00

PRESS RELEASE

   Surgeons at University of Florida evaluate use of Cellvizio during partial
                           and radical nephrectomies

    First clinical study to report the use of endomicroscopy to distinguish
        cancerous and normal tissue in small renal masses in real time

Paris, September 17, 2015 - Mauna Kea Technologies (Euronext: MKEA,
FR0010609263, PEA-SME eligible), inventor of Cellvizio(r), the multidisciplinary
confocal laser endomicroscopy (CLE) platform, today announced the publication of
clinical study results involving the use of CLE with Cellvizio in the peer
reviewed Journal of Urology. The investigators from the University of Florida,
College of Medicine, Gainesville, evaluated the ability of probe-based confocal
laser endomicroscopy (pCLE) to discriminate the various anatomic components of
human kidney tumors during radical or partial nephrectomies (kidney ablation).

The authors report for a cohort of 20 patients that ex vivo CLE imaging on fresh
specimen reveals normal renal structures with excellent correlation to
histology. Tumor tissues can be readily distinguished from normal parenchyma
with unique morphologic features to benign and malignant tumor subtypes
published here as a first reference atlas for small renal masses (SRM).

Most early stage kidney cancers are renal cell carcinomas (RCCs), and most are
diagnosed incidentally by imaging as SRM. SRM grew in incidence in recent
decades and pose an increasingly common management dilemma in urology, as
approximately 20% of these clinical stage 1 renal masses are benign and can
benefit from active surveillance, with less than 2% of patients progressing to
metastatic disease.

Doctor Li-Ming Su, Departments of Urology, University of Florida College of
Medicine, Gainesville, stated: "The detection of small incidental renal masses
is on the rise. Improved pre- and peri-operative diagnostics are needed to
differentiate tumors requiring aggressive treatment from those more suitable for
surveillance. Confocal laser endomicroscopy offers real time optical imaging
that correlates very well with histopathology as shown in our ex vivo kidney
tumor study. Our findings are a crucial stepping stone towards real time
diagnostic optical "biopsy" of renal tumors that may in the future provide more
relevant actionable data for better decision-making in the preoperative
setting."

"The results of these recent studies on the use of Cellvizio for the first time
in small renal masses add to the rapidly expanding body of literature confirming
the potential opportunities to use our unique technology in surgical oncology
including urology in order to rapidly and accurately identify the presence and
the extent of cancer in real time, potentially leading to a less invasive
procedure with patients left with a more functional kidney, and a much improved
quality of life" said Sacha Loiseau, founder and CEO of Mauna Kea Technologies.

About 80,000 nephrectomies are performed in the US annually and an estimated
160,000 worldwide.

About Mauna Kea Technologies
Mauna Kea Technologies is a global medical device company focused on protecting
patients' lives while enabling physicians and surgeons to make better decisions
thanks to direct visualization at the cellular level. The Company's flagship
product, Cellvizio, has received clearance to sell a wide range of applications
in more than 40 countries, including the United States, Europe, Japan, China,
Canada, Brazil and Mexico. For more information on Mauna Kea Technologies, visit
www.maunakeatech.com

Mauna Kea Technologies
Eric Cohen
Vice President Finance
Tel: +33 (0)1 70 08 09 70
investor-vpf@maunakeatech.com

France and Europe
NewCap - Investor Relations / Strategic Communication
Florent Alba/Pierre Laurent
Tel: +33 (0)1 44 71 94 94
maunakea@newcap.fr

MAUNA KEA TECHNOLOGIES's latest news

02/11/2023 08:00

MAUNA KEA TECHNOLOGIES (EPA:MKEA) Mauna Kea Technologies : Surgeons at University of Florida evaluate use of Cellvizio during partial and radical nephrectomies

Transparency directive : regulatory news

MAUNA KEA TECHNOLOGIES's latest news

Other stories